Determinants of left ventricular function improvement for cardiac resynchronization therapy candidates
Jung Ae Hong1,2, Sang Eun Lee1, Seon-Ok Kim3
1Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
ESC Heart Failure
|December 29, 2021
Summary
Early cardiac resynchronization therapy (CRT) may benefit some heart failure patients. However, left ventricular function improvement is rare, with higher mortality in CRT-indicated patients, suggesting individualized treatment timing.
Area of Science:
- Cardiology
- Heart Failure Management
Background:
- Standard practice recommends a waiting period before cardiac resynchronization therapy (CRT).
- Early CRT may be beneficial for select heart failure (HF) patients due to high mortality rates.
Purpose of the Study:
- To evaluate left ventricular (LV) function improvement rates and predictors in HF patients eligible for CRT.
- To assess the impact of CRT indications on patient outcomes and mortality.
Main Methods:
- Analysis of 1792 hospitalized acute HF patients with LVEF ≤ 35%.
- Patients categorized into: left bundle branch block (LBBB), wide QRS without LBBB, and control groups.
- Logistic regression and classification trees used to identify predictors of no LV function improvement.
Main Results:
- LV function improvement was observed in 24.3% (LBBB), 15.4% (wide QRS), and 40.5% (control) of patients.
- Patients meeting CRT indications had higher 3-month mortality (24.6% vs. 17.7%).
- Predictors of no improvement included large LV end-systolic dimension, low LVEF, insulin-treated diabetes, and suboptimal medical therapy.
Conclusions:
- Patients indicated for CRT exhibit higher mortality and rare LV function improvement, particularly with risk factors.
- The findings challenge the uniform waiting period for CRT, advocating for individualized treatment timing.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
50
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
50
Cardiomyopathy II: Dilated Cardiomyopathy
60
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
60
Cardiomyopathy V: Interprofessional Care
60
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
60
Cardiomyopathy III: Hypertrophic Cardiomyopathy
86
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
86
Heart Failure Drugs: Inotropic Agents
799
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
799
Heart Failure II: Pathophysiology
96
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
96


